IDEXX LABORATORIES INC (IX1.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:IX1 • US45168D1046
545.6 EUR
+11.6 (+2.17%)
Last: Feb 10, 2026, 07:00 PM
We assign a fundamental rating of 6 out of 10 to IX1. IX1 was compared to 63 industry peers in the Health Care Equipment & Supplies industry. IX1 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IX1 is valied quite expensively at the moment, while it does show a decent growth rate. This makes IX1 very considerable for quality investing!
1. Profitability
1.1 Basic Checks
- IX1 had positive earnings in the past year.
- IX1 had a positive operating cash flow in the past year.
- IX1 had positive earnings in each of the past 5 years.
- IX1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 30.34%, IX1 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- The Return On Equity of IX1 (65.81%) is better than 100.00% of its industry peers.
- IX1 has a better Return On Invested Capital (40.35%) than 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IX1 is significantly above the industry average of 9.98%.
- The 3 year average ROIC (37.60%) for IX1 is below the current ROIC(40.35%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- With an excellent Profit Margin value of 24.65%, IX1 belongs to the best of the industry, outperforming 92.06% of the companies in the same industry.
- In the last couple of years the Profit Margin of IX1 has grown nicely.
- With an excellent Operating Margin value of 31.34%, IX1 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of IX1 has grown nicely.
- IX1 has a better Gross Margin (61.72%) than 60.32% of its industry peers.
- In the last couple of years the Gross Margin of IX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IX1 is creating value.
- Compared to 1 year ago, IX1 has less shares outstanding
- The number of shares outstanding for IX1 has been reduced compared to 5 years ago.
- IX1 has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 21.78 indicates that IX1 is not in any danger for bankruptcy at the moment.
- The Altman-Z score of IX1 (21.78) is better than 100.00% of its industry peers.
- IX1 has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
- IX1's Debt to FCF ratio of 1.04 is amongst the best of the industry. IX1 outperforms 88.89% of its industry peers.
- IX1 has a Debt/Equity ratio of 0.53. This is a neutral value indicating IX1 is somewhat dependend on debt financing.
- IX1 has a Debt to Equity ratio (0.53) which is in line with its industry peers.
- Even though the debt/equity ratio score it not favorable for IX1, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.78 |
ROIC/WACC4.09
WACC9.86%
2.3 Liquidity
- IX1 has a Current Ratio of 1.18. This is a normal value and indicates that IX1 is financially healthy and should not expect problems in meeting its short term obligations.
- IX1 has a worse Current ratio (1.18) than 68.25% of its industry peers.
- IX1 has a Quick Ratio of 1.18. This is a bad value and indicates that IX1 is not financially healthy enough and could expect problems in meeting its short term obligations.
- IX1 has a worse Quick ratio (0.87) than 63.49% of its industry peers.
- IX1 does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 16.18% over the past year.
- The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
- Looking at the last year, IX1 shows a quite strong growth in Revenue. The Revenue has grown by 10.42% in the last year.
- Measured over the past years, IX1 shows a quite strong growth in Revenue. The Revenue has been growing by 9.72% on average per year.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- The Earnings Per Share is expected to grow by 15.88% on average over the next years. This is quite good.
- Based on estimates for the next years, IX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.00% on average per year.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y15.88%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y10%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 49.60, IX1 can be considered very expensive at the moment.
- IX1's Price/Earnings is on the same level as the industry average.
- The average S&P500 Price/Earnings ratio is at 28.03. IX1 is valued rather expensively when compared to this.
- A Price/Forward Earnings ratio of 43.77 indicates a quite expensive valuation of IX1.
- IX1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. IX1 is more expensive than 66.67% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, IX1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.6 | ||
| Fwd PE | 43.77 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IX1 indicates a slightly more expensive valuation: IX1 is more expensive than 65.08% of the companies listed in the same industry.
- IX1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.07 | ||
| EV/EBITDA | 35.26 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IX1 does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of IX1 may justify a higher PE ratio.
- IX1's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.71
PEG (5Y)3.48
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
- IX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IX1 (2/10/2026, 7:00:00 PM)
545.6
+11.6 (+2.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner ChangeN/A
Ins Owners0.21%
Ins Owner ChangeN/A
Market Cap43.57B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target692.16 (26.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)0.74%
PT rev (3m)38%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)0.19%
EPS NY rev (3m)7.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.15%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)3.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.6 | ||
| Fwd PE | 43.77 | ||
| P/S | 12.43 | ||
| P/FCF | 55.07 | ||
| P/OCF | 47.59 | ||
| P/B | 33.17 | ||
| P/tB | 50.14 | ||
| EV/EBITDA | 35.26 |
EPS(TTM)11
EY2.02%
EPS(NY)12.47
Fwd EY2.28%
FCF(TTM)9.91
FCFY1.82%
OCF(TTM)11.46
OCFY2.1%
SpS43.91
BVpS16.45
TBVpS10.88
PEG (NY)3.71
PEG (5Y)3.48
Graham Number63.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.78 |
F-Score8
WACC9.86%
ROIC/WACC4.09
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y15.88%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y10%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.21%
EBIT Next 3Y14.34%
EBIT Next 5Y15.67%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IX1.DE FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IX1.DE.
What is the valuation status of IDEXX LABORATORIES INC (IX1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to IDEXX LABORATORIES INC (IX1.DE). This can be considered as Overvalued.
What is the profitability of IX1 stock?
IDEXX LABORATORIES INC (IX1.DE) has a profitability rating of 9 / 10.
What is the financial health of IDEXX LABORATORIES INC (IX1.DE) stock?
The financial health rating of IDEXX LABORATORIES INC (IX1.DE) is 8 / 10.